ISTA Pharmaceuticals (ISTA -5.3%) trades lower after reporting mixed results from its eye drug...


ISTA Pharmaceuticals (ISTA -5.3%) trades lower after reporting mixed results from its eye drug trials. Phase 3 studies to evaluate the short-term safety and efficacy of its drug Remura, a treatment for dry eye disease, showed it was effective but not statistically better than the placebo.

From other sites
Comments (1)
  • TruffelPig
    , contributor
    Comments (4207) | Send Message
     
    If it isn't better than placebo we call that ineffective.
    13 Oct 2011, 01:14 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs